The functional interplay between cancer cells and immune cells is extremely complex. Immune cells initially inhibit tumor growth; however, tumor cells often suppress not only the tumor-inhibitory function of immune cells, but they can also hijack immune cells to promote tumor growth. In recent years, therapeutics aiming to restore the tumor suppression function of the immune system have shown impressive clinical results, but not all cancer patients benefit from these. This is an exciting time for the field of cancer immunology: basic science is having an important translational impact and immunotherapy is emerging as a major cancer therapeutic modality. However, there is a great deal to be learned about the interplay between cancer, inflammation, and immunity.
Cell Press is pleased to announce the second iteration of this symposium, thus providing a platform in which to share key advances and promote scientific collaboration. We will assemble leading experts to discuss basic immunology, cancer-immune cell interactions, and how tumor-associated inflammation can be reprogrammed for therapeutic benefit and to examine new approaches to cancer immunotherapy. Thus, we invite academic and industry scientists as well as clinicians to explore the key outstanding questions of tomorrow.
Using Elseviers new CELLCII2017 app, you can browse the scientific programme by days, topic or speaker, create your own personal programme, locate rooms and exhibitor stands on the floor plans, and more. Before first use, you will need to download the latest conference data and then afterwards, you can use the app offline.